Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-25 02:50 | 2025-11-20 | ALMS | Alumis Inc. | AKKARAJU SRINIVAS | Director | BUY | $7.20 | 125,743 | $905,350 | 643,260 |
| 2025-11-25 01:08 | 2025-11-20 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | BUY | $0.75 | 5,000 | $3,741 | 5,015 |
| 2025-11-25 01:47 | 2025-11-20 | JAZZ | Jazz Pharmaceuticals plc | McSharry Heather Ann | Director | OPT+S | $177.78 | 3,415 | $607,127 | 20,449 |
| 2025-11-25 00:09 | 2025-11-20 | TRDA | Entrada Therapeutics, Inc. | BAKER BROS. ADVISORS LP | 10% owner | BUY | $9.07 | 28,867 | $261,847 | 4,691,392 |
| 2025-11-25 00:15 | 2025-11-20 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $41.76 | 3,520 | $147,002 | 46,160 |
| 2025-11-25 00:02 | 2025-11-20 | SAVA | FILANA THERAPEUTICS, INC. | Barry Richard | Director, Officer | BUY | $2.76 | 150,000 | $414,000 | 938,060 |
| 2025-11-24 15:13 | 2025-11-21 | TTRX | Turn Therapeutics Inc. | GOLDEN ARTHUR F | Director | BUY | $2.87 | 20,532 | $58,927 | 50,734 |
| 2025-11-25 04:00 | 2025-11-24 | NUVL | Nuvalent, Inc. | Flynn James E | Director, 10% owner | SELL | $95.45 | 742,574 | $70,874,975 | 8,299,225 |
| 2025-11-22 00:00 | 2025-11-20 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,051.66 | 37,148 | $39,067,118 | 92,607,304 |
| 2025-11-22 01:43 | 2025-11-20 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | Officer | BUY | $2.89 | 2,450 | $7,075 | 10,000 |
| 2025-11-22 00:05 | 2025-11-19 | NUVB | Nuvation Bio Inc. | Hanley David C. | Officer | OPT+S | $7.14 | 200,000 | $1,427,680 | 24,000 |
| 2025-11-22 00:55 | 2025-11-19 | RPRX | Royalty Pharma plc | Lloyd George W. | Officer | SELL | $38.34 | 135,426 | $5,192,653 | 0 |
| 2025-11-22 02:34 | 2025-11-19 | ARQT | Arcutis Biotherapeutics Inc. | Matsuda Masaru | Officer | SELL | $28.29 | 2,550 | $72,135 | 151,476 |
| 2025-11-22 02:07 | 2025-11-20 | MLYS | Mineralys Therapeutics, Inc. | Slingsby Brian Taylor | Director, 10% owner | SELL | $43.35 | 1,000,000 | $43,350,000 | 7,903,838 |
| 2025-11-22 05:41 | 2025-11-20 | PRAX | Praxis Precision Medicines, Inc. | Nemiroff Alex | Officer | OPT+S | $193.09 | 25,130 | $4,852,256 | 20,832 |
| 2025-11-22 05:39 | 2025-11-20 | PRAX | Praxis Precision Medicines, Inc. | Mastrocola Lauren | Officer | OPT+S | $192.08 | 13,600 | $2,612,244 | 10,442 |
| 2025-11-22 01:28 | 2025-11-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $22.33 | 12,500 | $279,155 | 902,688 |
| 2025-11-22 04:22 | 2025-11-19 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Director | SELL | $20.23 | 1,300,000 | $26,304,460 | 18,047,727 |
| 2025-11-22 02:21 | 2025-11-20 | ARQT | Arcutis Biotherapeutics Inc. | Gilbert Halley E | Director | OPT+S | $27.55 | 16,532 | $455,442 | 22,123 |
| 2025-11-22 00:05 | 2025-11-20 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $35.83 | 5,784 | $207,244 | 363,151 |
| 2025-11-22 00:25 | 2025-11-19 | PVLA | PALVELLA THERAPEUTICS, INC. | Goin Kathleen | Officer | OPT+S | $86.23 | 4,302 | $370,965 | 0 |
| 2025-11-22 00:15 | 2025-11-19 | FULC | Fulcrum Therapeutics, Inc. | Gould Robert J | Director | SELL | $11.03 | 15,000 | $165,495 | 484,864 |
| 2025-11-22 02:35 | 2025-11-20 | SILO | Silo Pharma, Inc. | Weisblum Eric | Director, Officer | BUY | $0.37 | 2,000 | $735 | 211,932 |
| 2025-11-22 02:13 | 2025-11-20 | SGMT | Sagimet Biosciences Inc. | Kemble George | Director, Officer | SELL | $7.69 | 37,688 | $289,979 | 81,005 |
| 2025-11-21 16:45 | 2025-11-19 | SLS | SELLAS Life Sciences Group, Inc. | Kalin Katherine Bach | Director | BUY | $1.59 | 63,400 | $100,806 | 104,400 |
| 2025-11-22 01:07 | 2025-11-21 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner | BUY | $1.33 | 580,000 | $768,790 | 216,706,448 |
| 2025-11-22 05:52 | 2025-11-20 | ANNX | Annexon, Inc. | Satter Muneer A | Director | BUY | $4.38 | 822,613 | $3,600,824 | 9,728,637 |
| 2025-11-22 00:59 | 2025-11-19 | LFVN | Lifevantage Corp | BEINDORFF MICHAEL A | Director | SELL | $6.42 | 12,607 | $80,934 | 43,806 |
| 2025-11-22 03:57 | 2025-11-21 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | BUY | $3.50 | 20,000 | $69,900 | 2,490,539 |
| 2025-11-22 04:15 | 2025-11-19 | ROIV | Roivant Sciences Ltd. | QVT Financial LP | SELL | $20.23 | 1,300,000 | $26,304,460 | 18,047,727 | |
| 2025-11-22 04:24 | 2025-11-19 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Director | SELL | $20.23 | 1,300,000 | $26,304,460 | 18,047,727 |
| 2025-11-22 01:39 | 2025-11-21 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Huntsman Carole | Officer | SELL | $553.11 | 1,958 | $1,082,986 | 10,032 |
| 2025-11-22 03:54 | 2025-11-19 | PGEN | PRECIGEN, INC. | KIRK RANDAL J | Director, 10% owner | SELL | $4.14 | 2,966,293 | $12,291,725 | 5,554,244 |
| 2025-11-22 01:26 | 2025-11-20 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $476.51 | 8,000 | $3,812,082 | 130 |
| 2025-11-21 00:00 | 2025-11-19 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,051.17 | 167,526 | $176,098,707 | 92,644,452 |
| 2025-11-21 02:38 | 2025-11-18 | TENX | TENAX THERAPEUTICS, INC. | Giordano Christopher Thomas | Director, Officer | BUY | $7.68 | 2,605 | $20,000 | 2,605 |
| 2025-11-21 00:30 | 2025-11-18 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $30.03 | 35,656 | $1,070,710 | 174,998 |
| 2025-11-20 21:42 | 2025-11-19 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer | SELL | $25.00 | 10,000 | $250,000 | 139,025 |
| 2025-11-21 01:51 | 2025-11-18 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $0.92 | 160,103 | $147,919 | 5,321,436 |
| 2025-11-20 15:00 | 2025-11-18 | ITRM | Iterum Therapeutics plc | Dunne Michael W. | Director | BUY | $0.37 | 6,000 | $2,191 | 241,001 |
| 2025-11-21 00:00 | 2025-11-18 | SILO | Silo Pharma, Inc. | Weisblum Eric | Director, Officer | BUY | $0.40 | 12,000 | $4,847 | 209,932 |
| 2025-11-21 02:10 | 2025-11-20 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner | BUY | $1.33 | 580,000 | $771,342 | 216,126,448 |
| 2025-11-21 00:42 | 2025-11-20 | SLRX | Decoy Therapeutics Inc. | Rosenblum Mark J | Officer | BUY | $0.80 | 20,000 | $16,000 | 20,177 |
| 2025-11-21 00:05 | 2025-11-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $2.98 | 1,086 | $3,240 | 65,920 |
| 2025-11-21 00:05 | 2025-11-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Schwartz Jonathan David | Officer | SELL | $2.98 | 2,545 | $7,592 | 299,064 |
| 2025-11-21 00:05 | 2025-11-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Shah Gaurav | Director, Officer | SELL | $2.98 | 6,276 | $18,721 | 778,296 |
| 2025-11-21 00:05 | 2025-11-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $2.98 | 1,646 | $4,910 | 383,816 |
| 2025-11-21 00:00 | 2025-11-19 | LITS | Lite Strategy, Inc. | Flynn James P | Director | BUY | $1.88 | 12,100 | $22,777 | 30,000 |
| 2025-11-21 01:12 | 2025-11-19 | IONS | IONIS PHARMACEUTICALS INC | HERMAN JOAN E | Director | OPT+S | $72.13 | 44,000 | $3,173,830 | 46,086 |
| 2025-11-21 02:13 | 2025-11-18 | JAZZ | Jazz Pharmaceuticals plc | Carr Patricia | Officer | OPT+S | $182.06 | 5,319 | $968,402 | 7,012 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.